ReiThera collaborates with the MAGIC consortium to support the development of gene therapies for muscular dystrophies
ReiThera will be involved in setting up both Upstream Process (USP) and Downstream Process (DSP) conditions for GMP-compatible manufacturing of an AAV candidate specifically retargeted to muscle [...]
